NCT02130453View on ClinicalTrials.gov

Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking

PHASE4CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 28, 2024

Study Completion Date

June 28, 2024

Conditions
Ischemia
Interventions
DRUG

Regadenoson

0.4 mg by vein given during nuclear stress testing with echocardiography strain measurements.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Astellas Scientific & Medical Affairs, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02130453 - Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking | Biotech Hunter | Biotech Hunter